Patent ID: 11911444
Assignee: STRATATECH CORPORATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 8:
9. A method of treating a wound bed resulting from removal of a skin cancer in a patient, comprising:
a) providing a human skin substitute comprising cells expressing exogenous Interleukin-12, wherein the cells are selected from the group consisting of primary keratinocytes, keratinocyte precursors, transdifferentiated keratinocytes, and immortalized keratinocytes, wherein said skin substitute comprises a stratified squamous epithelium comprising said cells expressing exogenous Interleukin-12 supported on a dermal equivalent; and
b) placing said human skin substitute on said wound bed resulting from 9 removal of a skin cancer in said patient such that the dermal equivalent is in direct contact with the wound bed and separates the wound bed from the cells expressing exogenous Interleukin-12;
wherein the human skin substitute stimulates an immune response against residual cancer cells in the wound bed.